Veerhealth Care Q1 FY27 PAT jumps 5x, revenue up 456% YoY

Revenue growth above 20%Profit growth above 25%Related-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹46.95

prior close

₹48.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.3% vs market

Pharmaceuticals peers, median of 166sector-0.4%+0.2% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.7

15m

-1.6

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.1-0.3-0.4+0.2

Next day

+4.2+0.2+4.0-0.5+4.6

+2.3+0.6+1.7-0.6+2.8

+1.2-0.0+1.2-1.4+2.6

+4.3+0.5+3.8-0.9+5.2

+4.4+0.8+3.6-0.4+4.8

+2.0+0.6+1.4-0.9+2.9

15d

+5.4+1.3+4.2+0.0+5.4

+8.6-1.4+9.9-0.1+8.7

+5.8-0.6+6.4-2.8+8.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Veerhealth Care posted Q1 FY27 (quarter ended June 30, 2026) revenue from operations of Rs. 2,492.56 lakhs, up from Rs. 448.52 lakhs in the same quarter last year, a jump of about 456%. PAT rose to Rs. 122.66 lakhs from Rs. 24.06 lakhs. The board approved the director's report for FY26, fixed the 34th AGM for September 23, 2026, accepted the resignation of CS Ashita Chittora, and appointed Ruchi Shah as new CS. The company also issued 1 crore convertible warrants at Rs. 20.25.

Likely market impact

Strong top-line and bottom-line growth versus last year. Appointment of new CS is a related-party hire, which may raise governance questions.